This website is intended exclusively for healthcare professionals and medical device manufacturers.
By accessing this site, you confirm that you belong to one of its of these categories and understand that the information provided is specifically intented for a professional audience.
"THE EXOSOMES MARKET"
Jean-Yves Coste is Co-founder, Partner and Chairman of WINDOME BANKING PARTNERS.
He has over 30 years’ experience in healthcare investment banking and in executive positions in corporate environments.
Prior to co-founding WINDOME BANKING PARTNERS, he was Senior Healthcare Director at Michel Dyens & Co, a Franco-American investment bank specialising in cross-border M&A, capital raising and partnerships, covering sectors such as specialty generics, biotechnology, prophylactic and therapeutic vaccines, medtech, digital health and regenerative medicine. From 2008 to 2010, he was Senior M&A Adviser at Bryan, Garnier, an investment bank specialising in the healthcare, media, luxury goods and technology sectors. Prior to that, he headed up Cowen’s European healthcare investment banking business in London, strengthening the company’s healthcare franchise in Europe. In 2003, he joined the Big Pharma Boehringer Ingelheim to head up the M&A department, gaining first-hand expertise with the world’s top 20 pharmaceutical companies.
His investment banking career began at Deutsche Bank in Frankfurt in 1996, where he specialised in the pharmaceutical and biotech sectors. Between 2000 and 2003, he joined Deutsche Bank Securities in New York, a pioneer in the execution of cross-border M&A transactions in the fields of life sciences, molecular diagnostics, genomics and genetic medicine. He has accumulated recognised expertise in transactions focused on the prevention, therapy and management of age-related chronic degenerative diseases, as well as in aesthetic and regenerative medicine.
He worked notably on such major transactions such as BloomageRevitacare, Bridgepoint-Vivacy, MatexLab-Abris Capital, Suisselle-Sihuan Pharma Partnership, Delife-Menarini, Croma US-JV with Hugel Corp, and MatexLab’s entry into licensing partnership with a Chinese Aesthetics player, as well as co-advising private equity funds in the development of their aesthetic and dermatological care franchises.
Since 2012, he is a Speaker at IMCAS’ World Industry Tribune, where he presents M&A and valuation trends in aesthetic medicine, the American Aesthetic Innovation Summit (AIS), the Global Virtual Aesthetic Summit (GVAS), the Assises de l’Innovation en Medecine Esthétique (AIME) as well as the Thinkin Injectable Summit aunched by Dr. Benjamin Ascher in October 2024.
A graduate of HEC Paris with a specialisation in Finance, Jean-Yves Coste also holds an MBA from INSEAD, specialising in investment banking.
Exosomes, extracellular vesicles that facilitate intercellular communication, are gaining significant traction in regenerative medical aesthetics. Known for their ability to repair tissue, stimulate collagen and elastin synthesis, reconstruct the dermal-epidermal juncture and accelerate the mitochondrial activity of the cell, thus promoting skin rejuvenation, exosomes are becoming a cornerstone of non-invasive aesthetic treatments.
Their ultrasmall size (30 to 150 nanometers) facilitates the penetration of the stratum corneum and their targeted delivery as tissular inductors.
Plant Derived Exosomes offer unique morphological and compositional characteristics as natural nanocarriers at the core of intercellular cross-talk. They can exercise a biotherapeutic role by elucidating their immunological modulating, anti-tumor, regenerative, and anti-inflammatory roles.
Plant exosomes have superior plasticity enabling them to reengineer nanovesicles into robust, innocuous, and non-immunogenic nanovectors for drug delivery through multiple stringent biological hindrances to various targeted organs such as the intestine and the brain.
The global exosomes market reached US$ 500m in 2024, with 60% for diagnostics and 40% for therapeutics with a gradual shift of the center of gravity towards therapeutics with an initial focus on cardiovascular, metabolic, oncological, respiratory and anti-inflammatory areas but are now augmenting their impact on age-related dermatological pathologies. It is scheduled to explode to US$ 3bn by 2030, eg a 28% Compounded Annual Growth Rate.
It dominates the exosomes market, thanks to its advanced healthcare infrastructure, robust biotechnology ecosystem, and growing demand for aesthetic treatments. The U.S. leads this region, (ca US$ 250m revenues in 2024) driven by early adoption of innovative technologies and high disposable incomes followed by Canada.
Europe represents the second-largest market, fueled by innovation and consumer interest in minimally invasive procedures. Countries such as Germany, the UK, and France are key players, with a strong emphasis on research and development. Southern European nations are benefiting from the rising popularity of medical tourism, although stringent regulatory frameworks can slow market entry for new products.
Is experiencing the fastest growth, driven by high demand for aesthetic procedures in South Korea, Japan, and China. South Korea leads the charge with its advanced cosmetic industry and adoption of regenerative treatments, but China is catching up. Chinese National Development and Reform Commission (NDRC) issued the “14th Five-Year Plan for Biological Economy Development”, in which “exosomal therapeutic products” entered the national economic development plan for the first time; exosomes were mentioned again in “Biological Economy Innovation Capability Enhancement Project” and in “Biological Economy Innovation Capability Enhancement Project”, “Exosome Therapeutic Products” and has become a recurrent leitmotiv in the “14th Five-Year Plan for Biological Economy Development” .Growing disposable incomes and the expansion of medical tourism in India, Indonesia and Thailand also support market growth.
Latin America is an emerging market, with Brazil and Mexico leading the way. These countries have a strong culture of aesthetic procedures and attract medical tourists due to affordable treatments. However, economic instability and limited access to advanced technologies may constrain growth in some parts of the region.
The MEA region, particularly Turkey as a medical aesthetic hub and the Gulf Cooperation Council (GCC) countries, is beginning to adopt exosome-based therapies. Investments in healthcare infrastructure and rising interest in medical tourism are driving market growth, especially in the UAE. However, challenges such as limited awareness and underdeveloped medical systems in parts of Africa remain barriers to expansion.
The exosomes market in regenerative aesthetics promises strong growth, driven by innovation and increasing demand. Despite certain challenges, their combination with technologies such as lasers and radiofrequency paves the way for transformative and personalised results.
